Skip To Main Content
Joshua Rosenblat on Muck Rack

Joshua Rosenblat

  • Senior Editor, Shopify
Chicago
As seen in: The New York Times, Color Research & Application, Nature, Memory Studies, Evidence-Based Mental Health, Sports Illustrated, Taylor & Francis Online, U.S. News and World Report, JAMA Psychiatry, The Philadelphia Inquirer and
Covers:  ncaa basketball, northwestern sports, nba, sports
@shopify growth and content Past: @SInow, @phillyinquirer, @nytimes, @espn (he/him/his)

Get in touch with Joshua

Contact Joshua, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Joshua Rosenblat’s Biography

Read Full Bio →

On a Sunday evening in early November, my friends and I sat in my family room sprawled on the couch. A largely ignored NFL game lit up the television screen as we joked and laughed. At one point, I opened my mouth to begin to tell a story and one of my friends interrupted me, “Josh, I just have to say, I love when you tell stories. They’re great.” I took the compliment in passing and continued with the mostly inconsequential story. I didn’t realize the significance behind my friend’s remark unt…

Articles

Psychedelics Trials and Outcomes—A Closer Look

|
By Robin Carhart-Harris, Joshua Rosenblat
| JAMA Psychiatry Verified
To the Editor In the article by Williams et al1 in JAMA Psychiatry, comparison of efficacy data from (mostly double-blind randomized clinical trials) of psychedelic therapy (PT) vs open-label trials (OLTs) of traditional antidepressants (TADs) rests on flawed assumptions. One is that a lack of blinding activates expectancy as the main driver of efficacy.
Open in Who Shared Issue with article?

Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder : A Randomized Clinical Trial

|
By Hartej Gill, Sebastian Badulescu, Ryan M. Brudner, Lee Phan, Joshua Di Vincenzo, Aniqa Tabassum, Sharmili Edwin Thanarajah, Cristian-Daniel Llach, Joshua Rosenblat, Roger S. McIntyre, Rodrigo B. Mansur, Hiya Shah
| JAMA Psychiatry Verified
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial Key Points Question Does oral semaglutide improve reward-related dysfunction in a clinical population with major depressive disorder (MDD)? Findings In this 16-week, double-blind, placebo-controlled, parallel-group, fixed-dose randomized clinical trial, semaglutide-treated participants exhibited a pattern of increased willingness to exert physical efforts with higher expected values of reward.
Open in Who Shared Issue with article?

Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence - Molecular Psychiatry

|
By Cristian-Daniel Llach, Gia Lê, Joshua Rosenblat
| Nature Verified
Abstract Bipolar disorder (BD) is a chronic and disabling psychiatric illness characterized by complex pathophysiological mechanisms. Traditional treatments often fail to address these multidimensional processes, highlighting the need for novel therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for metabolic disorders, have emerged as promising candidates for a range of neuropsychiatric conditions due to their broad neurobiological effects.
Open in Who Shared Issue with article?
See all 147 licensed articles (148 Total)